Jan E. De Vries

Biography

Prior to joining AIMM’s Board of Directors in 2010 and becoming CEO in 2012, Jan de Vries served as vice president and head of the Novartis Research Institutes for Biomedical Research (Basel, Switzerland). While at Novartis, de Vries steered the discovery and early development of many drugs including: Elidel, Ilaris (Canakunimab), Gilenya and Secukinumab. Prior to Novartis, de Vries served as director of the California-based DNAX Research Institute for Molecular Biological Research (acquired by Schering-Plough and Merck & Co) and co-director of the Schering–Plough Institute for Immunological Research in Lyon, France.

Research Interest

Prior to joining AIMM’s Board of Directors in 2010 and becoming CEO in 2012, Jan de Vries served as vice president and head of the Novartis Research Institutes for Biomedical Research (Basel, Switzerland). While at Novartis, de Vries steered the discovery and early development of many drugs including: Elidel, Ilaris (Canakunimab), Gilenya and Secukinumab. Prior to Novartis, de Vries served as director of the California-based DNAX Research Institute for Molecular Biological Research (acquired by Schering-Plough and Merck & Co) and co-director of the Schering–Plough Institute for Immunological Research in Lyon, France.